Revolutionary New Medication Shows Promise for Instant Migraine Relief

A drug recently approved to prevent migraine may start working right away, according to a new study. The study looked at the drug atogepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist taken by mouth. A drug recently approved to prevent migraine may start working right away, according to a study published in the
HomeDiseaseCOVIDCOVID-19 Virus: Threat to Vision as it Penetrates Blood-Retinal Barrier

COVID-19 Virus: Threat to Vision as it Penetrates Blood-Retinal Barrier

Researchers have found that the virus responsible for COVID-19 has ‍the ability to‌ break through the protective blood-retinal barrier, which could have⁤ long-term ‌effects​ on the eye. The blood-retinal barrier is meant to safeguard our vision by preventing microbial pathogens from reaching the retina and causing inflammation that could lead to vision loss. However, researchers at⁢ the University of Missouri School of ⁢Medicine⁤ have found that the COVID-19 virus can⁤ bypass this protective barrier, posing potential risks ​for the eye.Dr. Singh, a PhD and assistant professor of ophthalmology, ⁣is leading a research team aiming to find new ways to prevent and treat ocular infectious diseases. The team used ‌a humanized ACE2 mice model and discovered that the virus responsible​ for ‍COVID-19, SARS-CoV-2,⁢ can ‍infect ⁣the interior of the​ eyes even if it doesn’t enter the body through the eye surface. Instead, they ​found that when the virus enters the⁢ body through inhalation,⁢ it not only infects organs such as the lungs but also reaches the eyes through the blood-retinal barrier by infecting the cells that line this barrier.

“This discovery is ‌significant as we enhance our understanding‌ of the ​virus’s behavior.Understanding the long-term ‍effects of SARS-CoV-2 infection is crucial,” Singh stated. Previously, researchers ‌focused on ⁤the virus’s impact on ⁢the ocular surface. However, ‍our research shows that SARS-CoV-2 not only reaches the eye during systemic ​infection but also triggers an​ intense⁣ inflammatory response in the retina,⁤ leading to cell death in the blood-retinal barrier.⁣ The longer the virus remains in the eye, the greater the risk of damage‍ to the‌ retina and visual ⁤function.

Singh also found that prolonged ⁣presence of ‌SARS-CoV-2 spike antigen can lead to retinal microaneurysm, retinal artery and vein ​occlusion, and vascular leakage.”

We suggest that individuals diagnosed with COVID-19 should consult their ophthalmologist to check for any potential changes ​to the retina,” Singh recommended. “Even those who did not show symptoms could experience⁤ eye⁤ damage over time due to COVID-19 complications.”

Prior research has shown that viruses and bacteria‍ can breach the blood-retinal-barrier in immunocompromised individuals, but this study is the first to indicate that ⁣the virus responsible for COVID-19 might breach the barrier in otherwise healthy people, ⁤leading to an infection within the eye. This⁤ could be particularly concerning for immunocompromised patients or those with high risk.Untreated⁣ individuals with hypertension or diabetes may face more severe outcomes ⁣if they are not diagnosed with COVID-19 related eye symptoms. “Now that‍ we are aware of the​ danger of COVID-19 to the retina, our objective is to gain a better understanding of the ‍cellular and ​molecular⁣ mechanisms by which ⁣this virus penetrates the blood-retinal barrier and the resulting pathological ‌effects, with the hope of influencing the creation of therapies to prevent and treat ⁤COVID-19 induced eye complications before a patient’s ‍vision is affected,” Singh ​stated. ‍The study, titled “SARS-CoV-2 infects cells lining the⁤ blood-retinal barrier and induces a ​hyperinflammatory immune response, aims to advance ​knowledge in ⁤this area.An article​ titled ⁣”Novel Epithelial Insights Into The Mechanisms ​of Vesicular Stomatitis Virus Retinopathy” was recently‌ published in PLOS Pathogens. The University of‌ Missouri School of Medicine’s research team, which included Vaishnavi Balendiran, MD, Monu Monu, Faraz ⁢Ahmad, and Rachel ⁤M. ​Olson, PhD, Chief ⁤Scientific Officer, Laboratory for Infectious Disease Research at the College of‍ Veterinary Medicine, conducted the study. The research was supported by funding from the University​ of‍ Missouri and the National Institutes‌ of Health (NIH)/National ‌Eye Institute (NEI) grant R01EY032495.